Navigation Links
Halozyme Therapeutics To Present At The 32nd Annual J.P. Morgan Healthcare Conference
Date:1/9/2014

SAN DIEGO, Jan. 9, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2014 at 10:00 a.m. PT / 1:00 p.m. ET. Helen Torley, M.B. Ch. B., M.R.C.P., President and Chief Executive Officer of Halozyme Therapeutics, will provide a corporate overview.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
2. Public Offerings of Common Stock, Financial Results, and Significant Progress in Key Development Programs - Research Report on BioCryst, Exelixis, Idenix, Puma Biotechnology, and Halozyme
3. Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
4. Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call
5. Halozyme to Host Second Quarter Financial Results Conference Call
6. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
7. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
8. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
9. Sorrento Therapeutics Welcomes William S. Marth as Chairman of the Board of Directors
10. Spark Therapeutics Expands Leadership Team to Support Development and Commercialization of its Late-Stage Gene Therapy Pipeline
11. Adheron Therapeutics Announces Favorable Phase 1 Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... CannLabs, Inc. (OTCQB: CANL), the ... testing methodologies relating to cannabis, today announced that it ... credit from an existing stockholder of the Company. ... commitment from one of our existing stockholders,” stated ... will help accelerate our planned expansions into the Connecticut ...
(Date:11/22/2014)... , Nov. 21, 2014  The element of ... emerging diseases, i.e., they strike without warning. Until now, ... warning of a viral outbreak, resulting in suboptimal responses ... Ebola currently. Photo - http://photos.prnewswire.com/prnh/20141121/160242 ... has now been removed because virus gene structural changes ...
(Date:11/21/2014)... November 20, 2014 Offering a complete ... Sartorius Entris Balance promotion . The Sartorius Entris Balance ... durable, high accuracy, and easy-to-maintain balance entry level balance. ... It was designed to help customer’s bridge the gap ... balance that is very durable. Sartorius is the second ...
(Date:11/21/2014)... Arkansas (PRWEB) November 20, 2014 ... Pinnacle Ozone Solutions, LLC (Pinnacle), and PCI, Inc., ... announced that they have been selected to provide ... of Fayetteville, Arkansas Paul R. Noland Wastewater Treatment. ... BlueInGreen’s patented HyDOZ® gas dissolution technology, ...
Breaking Biology Technology:CannLabs Secures $750,000 Line Of Credit 2Viruses' Advantage of Surprise is Lost 2Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4
... of,streamers this morning, the most famous mouse in the ... Hospital from Walt Disney,World and Disney Worldwide Outreach. With ... hospital, The Walt Disney Company and Florida Children,s,Hospital revealed ... for,the "Children,s Hospital of the Future." While The ...
... KONG, Sept. 19 /Xinhua-PRNewswire/ -- Shanghai Century (Amex:,SHA), ... Sichuan,Kelun Pharmaceutical Co., Ltd (Kelun), China,s largest producer ... with,unaudited financial highlights with respect to the consolidated ... variable interest entity,(Kelun Group) for the first half ...
... Commercialization and Supply Agreement, Company to Host Conference Call at 12:30 p.m. ... ... 2007, LEXINGTON, Mass., Sept. 19 Indevus,Pharmaceuticals, Inc. (Nasdaq: ... acquisition of Esprit Pharma, has obtained the,United States rights to SANCTURA(R) and ...
Cached Biology Technology:Florida Children's Hospital and Disney Unite to Create Magical Pediatric Hospital 2Florida Children's Hospital and Disney Unite to Create Magical Pediatric Hospital 3Florida Children's Hospital and Disney Unite to Create Magical Pediatric Hospital 4Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 2Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 3Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 4Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 5Indevus Announces Allergan as New Partner for SANCTURA Brand 2Indevus Announces Allergan as New Partner for SANCTURA Brand 3Indevus Announces Allergan as New Partner for SANCTURA Brand 4Indevus Announces Allergan as New Partner for SANCTURA Brand 5Indevus Announces Allergan as New Partner for SANCTURA Brand 6
(Date:11/7/2014)... Dr. Debra Auguste, associate professor, biomedical engineering, in ... College of New York, have identified a molecule ... of the most aggressive forms of breast cancer. ... high mortality rate owing to aggressive proliferation and ... However, Professor Auguste,s team, discovered the overexpression of ...
(Date:11/6/2014)... a team of Florida State University biologists could lead ... to and survive environmental swings such as droughts or ... of the journal The Plant Cell , sheds ... proteins) is organized in a cell and how plants ... on and others are turned off. , "If you ...
(Date:11/6/2014)... - Insilico Medicine, Inc, a Baltimore-based bioinformatics company ... diseases announced a research collaboration with the international ... Inc (OTC: CSBR). , "There are many companies ... Champions Oncology,s TumorGraft technology is unique in a ... experimentally generating vast amounts of valuable data. Our ...
Breaking Biology News(10 mins):Maize analysis yields whole new world of genetic science 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... COLUMBIA, Mo. Asian-American youth are one of the ... Americans begin smoking later in life, they are more ... than other ethnic or racial groups, according to the ... of Missouri researcher is examining the unique differences in ...
... acclaimed scientist, explorer and conservationist, will receive the Academy ... today. He is the first Australian to receive the ... Australia,s leading thinkers and writers, Flannery has discovered more ... He has published more than 130 peer-reviewed scientific papers ...
... research has provided the first evidence that ,gender bending, chemicals ... oceans can have a significant impact on the ability of ... the four year study, led by the universities of Exeter ... these chemicals on ecosystem health and possibly on humans. ...
Cached Biology News:School attendance, refusal skills combat smoking risk in youth 2Scientist Tim Flannery is first Austrailian to receive Joseph Leidy Award 2Research proves 'gender-bending' chemicals affect reproduction 2
Peptide-affinity Purified Polyclonal Antibody to Olfactory Receptor, Family 2, Subfamily H, Member 3...
Molecular Biological Resources offers bulk quantities of existing protein products. Please see the Chimerx divisions website for existing products and contact lloconne@molbiores.com for pricing....
... from balances and scales with RS232 ports and ... If you can type the weight into the ... Simple to use parser extracts required data ... user information , Collect data at timed intervals ...
Peptide-affinity Purified Polyclonal Antibody to Prolactin Releasing Hormone Receptor (GPR10)...
Biology Products: